# US 2016/0361283 A1 · Isoprenyl Compounds and Methods Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0361283 A1
- Document ID: US20160361283A1
- Status: Published application
- Kind: A1
- Application number: 15/151,221
- Filed: 2016-05-10
- Published: 2016-12-15
- Earliest claimed: 2008-11-11
- Assignees: Signum Biosciences, Inc.
- Applicants: Signum Biosciences, Inc.
- Inventors: Jeffry B. Stock; Maxwell Stock; Keshava Rapole; Seung-Yub Lee; Michael Voronkov; Eduardo Perez; Joel Gordon; Shuyi Chen; Jinglong Chen
- Web page: https://patentgrep.com/patent/US20160361283A1

## CPC

- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 17/08: Antiseborrheics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07C 243/34: to carbon atoms of a carbon skeleton further substituted by nitrogen atoms
- C07C 321/18: of an acyclic unsaturated carbon skeleton
- C07C 323/59: with acylated amino groups bound to the carbon skeleton
- C07C 335/08: of a saturated carbon skeleton
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 209/18: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 209/48: with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C07D 217/26: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 243/34: containing a quinazoline or hydrogenated quinazoline ring system
- C07D 295/145: with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D 307/54: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 333/24: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07C 2601/02: with a three-membered ring
- C07C 2601/14: The ring being saturated
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.

## Claims

### Claim at position 1

-36. (canceled)

### Claim 37

A pharmaceutically acceptable salt of the compound 4-(1-carboxy-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)ethylamino)-4-oxobutanoic acid, having the formula:

### Claim 38 (depends on 37)

A pharmaceutical composition, comprising the pharmaceutically acceptable salt according to claim 37 and one or more pharmaceutically acceptable carriers.

### Claim 39 (depends on 38)

The pharmaceutical composition according to claim 38, wherein said pharmaceutically acceptable salt of 4-(1-carboxy-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)ethylamino)-4-oxobutanoic acid comprises at least 75% of a pharmaceutically acceptable salt of 4-((R)-1-carboxy-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)ethylamino)-4-oxobutanoic acid.

### Claim 40 (depends on 39)

The pharmaceutical composition according to claim 39, wherein said pharmaceutically acceptable salt of 4-(1-carboxy-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)ethylamino)-4-oxobutanoic acid comprises at least 80% of a pharmaceutically acceptable salt of 4-((R)-1-carboxy-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)ethylamino)-4-oxobutanoic acid.

### Claim 41 (depends on 40)

The pharmaceutical composition according to claim 40, wherein said pharmaceutically acceptable salt of 4-(1-carboxy-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)ethylamino)-4-oxobutanoic acid comprises at least 85% of a pharmaceutically acceptable salt of 4-((R)-1-carboxy-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)ethylamino)-4-oxobutanoic acid.

### Claim 42 (depends on 41)

The pharmaceutical composition according to claim 41, wherein said pharmaceutically acceptable salt of 4-(1-carboxy-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)ethylamino)-4-oxobutanoic acid comprises at least 90% of a pharmaceutically acceptable salt of 4-((R)-1-carboxy-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)ethylamino)-4-oxobutanoic acid.

### Claim 43 (depends on 42)

The pharmaceutical composition according to claim 42, wherein said pharmaceutically acceptable salt of 4-(1-carboxy-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)ethylamino)-4-oxobutanoic acid comprises at least 95% of a pharmaceutically acceptable salt of 4-((R)-1-carboxy-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)ethylamino)-4-oxobutanoic acid.

### Claim 44 (depends on 43)

The pharmaceutical composition according to claim 43, wherein said pharmaceutically acceptable salt of 4-(1-carboxy-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)ethylamino)-4-oxobutanoic acid comprises at least 97.5% of a pharmaceutically acceptable salt of 4-((R)-1-carboxy-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)ethylamino)-4-oxobutanoic acid.

### Claim 45 (depends on 38)

The pharmaceutical composition according to claim 38, wherein said pharmaceutical composition is in a form suitable for oral, parenteral, urethral, vaginal, nasal, topical, pulmonary, deep lung, inhalation, buccal, or sublingual administration to a subject.

### Claim 46 (depends on 45)

The pharmaceutical composition according to claim 45, wherein said pharmaceutical composition is in a form suitable for oral, parenteral, or topical administration to a subject.

### Claim 47 (depends on 46)

The pharmaceutical composition according to claim 46, wherein said pharmaceutical composition is in a form suitable for topical administration to a subject.

### Claim 48 (depends on 47)

The pharmaceutical composition according to claim 47, wherein said pharmaceutical composition is in the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil.

### Claim 49 (depends on 48)

The pharmaceutical composition according to claim 48, wherein said pharmaceutical composition is in the form of an ointment, cream, lotion, paste, or gel.

### Claim 50

A method of treating a disease or condition in a subject, comprising administering to said subject a pharmaceutically acceptable salt of 4-(1-carboxy-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)ethylamino)-4-oxobutanoic acid, wherein said disease or condition is associated with an inflammatory response in said subject.

### Claim 51 (depends on 50)

The method according to claim 50, wherein said pharmaceutically acceptable salt of 4-(1-carboxy-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)ethylamino)-4-oxobutanoic acid is an alkali or alkaline earth salt.

### Claim 52 (depends on 51)

The method according to claim 51, wherein said pharmaceutically acceptable salt is selected from the group consisting of sodium, lithium, potassium, calcium and magnesium salt.

### Claim 53 (depends on 52)

The method according to claim 52, wherein said pharmaceutically acceptable salt is the sodium salt.

### Claim 54 (depends on 50)

The method according to claim 50, wherein said pharmaceutically acceptable salt of 4-(1-carboxy-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)ethylamino)-4-oxobutanoic acid is administered to said subject in the form of a pharmaceutical composition.

### Claim 55 (depends on 54)

The method according to claim 54, wherein said pharmaceutical composition is administered to said subject by oral, parenteral, urethral, vaginal, nasal, topical, pulmonary, deep lung, inhalation, buccal, or sublingual administration.

### Claim 56 (depends on 55)

The method according to claim 55, wherein said pharmaceutical composition is administered to said subject by oral, parenteral, or topical administration.

### Claim 57 (depends on 56)

The method according to claim 56, wherein said pharmaceutical composition is administered to said subject by topical administration.

### Claim 58 (depends on 50)

The method according to claim 50, wherein said disease or condition is an inflammatory skin condition.

### Claim 59 (depends on 58)

The method according to claim 58, wherein said inflammatory skin condition is selected from rosacea, psoriasis, atopic dermatitis, and seborrhic dermatitis.

### Claim 60 (depends on 54)

The method according to claim 54, wherein said disease or condition is an inflammatory skin condition.

### Claim 61 (depends on 60)

The method according to claim 60, wherein said inflammatory skin condition is selected from rosacea, psoriasis, atopic dermatitis, and seborrhic dermatitis.

### Claim 62 (depends on 61)

The method according to claim 61, wherein said inflammatory skin condition is rosacea.

### Claim 63 (depends on 61)

The method according to claim 61, wherein said inflammatory skin condition is psoriasis.

### Claim 64 (depends on 61)

The method according to claim 61, wherein said inflammatory skin condition is atopic dermatitis.

### Claim 65 (depends on 61)

The method according to claim 61, wherein said inflammatory skin condition is seborrhic dermatitis.

### Claim 66 (depends on 50)

The method according to claim 50, wherein said pharmaceutically acceptable salt of 4-(1-carboxy-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)ethylamino)-4-oxobutanoic acid is administered to said subject in an amount from about 0.001 mg to about 100 mg per kilogram of subject weight per day.

### Claim 67

A pharmaceutically acceptable salt of the compound having the formula:

### Claim 68 (depends on 67)

The pharmaceutically acceptable salt according to claim 67, wherein said pharmaceutically acceptable salt is an alkali or alkaline earth salt.

### Claim 69 (depends on 68)

The pharmaceutically acceptable salt according to claim 68, wherein said salt is selected from the group consisting of sodium, lithium, potassium, calcium and magnesium salt.

### Claim 70 (depends on 69)

The pharmaceutically acceptable salt according to claim 69, wherein said salt is the sodium salt.

### Claim 71 (depends on 67)

A pharmaceutical composition, comprising the pharmaceutically acceptable salt according to claim 67 and one or more pharmaceutically acceptable carriers.

### Claim 72 (depends on 71)

The pharmaceutical composition according to claim 71, wherein said pharmaceutical composition is in a form suitable for oral, parenteral, urethral, vaginal, nasal, topical, pulmonary, deep lung, inhalation, buccal, or sublingual administration to a subject.

### Claim 73 (depends on 72)

The pharmaceutical composition according to claim 72, wherein said pharmaceutical composition is in a form suitable for oral, parenteral, or topical administration to a subject.

### Claim 74 (depends on 73)

The pharmaceutical composition according to claim 73, wherein said pharmaceutical composition is in a form suitable for topical administration to a subject.

### Claim 75 (depends on 74)

The pharmaceutical composition according to claim 74, wherein said pharmaceutical composition is in the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil.

### Claim 76 (depends on 75)

The pharmaceutical composition according to claim 75, wherein said pharmaceutical composition is in the form of an ointment, cream, lotion, paste, or gel.

### Claim 77

A method of treating a disease or condition in a subject, comprising administering to said subject a pharmaceutically acceptable salt of a compound having the formula:
wherein said disease or condition is associated with an inflammatory response in said subject.

### Claim 78 (depends on 77)

The method according to claim 77, wherein said pharmaceutically acceptable salt is an alkali or alkaline earth salt.

### Claim 79 (depends on 78)

The method according to claim 78, wherein said pharmaceutically acceptable salt is selected from the group consisting of sodium, lithium, potassium, calcium and magnesium salt.

### Claim 80 (depends on 79)

The method according to claim 79, wherein said pharmaceutically acceptable salt is the sodium salt.

### Claim 81 (depends on 77)

The method according to claim 77, wherein said pharmaceutically acceptable salt is administered to said subject in the form of a pharmaceutical composition.

### Claim 82 (depends on 81)

The method according to claim 81, wherein said pharmaceutical composition is administered to said subject by oral, parenteral, urethral, vaginal, nasal, topical, pulmonary, deep lung, inhalation, buccal, or sublingual administration.

### Claim 83 (depends on 82)

The method according to claim 82, wherein said pharmaceutical composition is administered to said subject by oral, parenteral, or topical administration.

### Claim 84 (depends on 83)

The method according to claim 83, wherein said pharmaceutical composition is administered to said subject by topical administration.

### Claim 85 (depends on 77)

The method according to claim 77, wherein said disease or condition is an inflammatory skin condition.

### Claim 86 (depends on 85)

The method according to claim 85, wherein said inflammatory skin condition is selected from rosacea, psoriasis, atopic dermatitis, and seborrhic dermatitis.

### Claim 87 (depends on 81)

The method according to claim 81, wherein said disease or condition is an inflammatory skin condition.

### Claim 88 (depends on 87)

The method according to claim 87, wherein said inflammatory skin condition is selected from rosacea, psoriasis, atopic dermatitis, and seborrhic dermatitis.

### Claim 89 (depends on 88)

The method according to claim 88, wherein said inflammatory skin condition is rosacea.

### Claim 90 (depends on 88)

The method according to claim 88, wherein said inflammatory skin condition is psoriasis.

### Claim 91 (depends on 88)

The method according to claim 88, wherein said inflammatory skin condition is atopic dermatitis.

### Claim 92 (depends on 88)

The method according to claim 88, wherein said inflammatory skin condition is seborrhic dermatitis.

### Claim 93 (depends on 77)

The method according to claim 77, wherein said pharmaceutically acceptable salt is administered to said subject in an amount from about 0.001 mg to about 100 mg per kilogram of subject weight per day.
